Top

BMC Cancer

Published in:

Open Access 01-12-2011 | Research article

Association between novel PLCE1variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck

Authors: Hongxia Ma, Li-E Wang, Zhensheng Liu, Erich M Sturgis, Qingyi Wei

Published in: BMC Cancer | Issue 1/2011

Abstract

Background

Phospholipase C epsilon 1 (PLCE1) (an effector of Ras) belonging to the phospholipase family plays crucial roles in carcinogenesis and progression of several cancers, including squamous cell carcinoma of the head and neck (SCCHN). A single nucleotide polymorphism (SNP, rs2274223) in PLCE1 has been identified as a novel susceptibility locus in genome-wide association studies (GWAS) of esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA) that share similar risk factors with SCCHN. Therefore, we investigated the association between potentially functional SNPs in PLCE1 and susceptibility to SCCHN.

Methods

We genotyped three potentially functional SNPs (rs2274223A/G, rs3203713A/G and rs11599672T/G) of PLCE1 in 1,098 SCCHN patients and 1,090 controls matched by age and sex in a non-Hispanic white population.

Results

Although none of three SNPs was alone significantly associated with overall risk of SCCHN, their combined effects of risk alleles (rs2274223G, rs3203713G and rs11599672G) were found to be associated with risk of SCCHN in a locus-dose effect manner (P _trend = 0.046), particularly for non-oropharyngeal tumors (P _trend = 0.017); specifically, rs2274223 was associated with a significantly increased risk (AG vs. AA: adjusted OR = 1.29, 95% CI = 1.01-1.64; AG/GG vs. AA: adjusted OR = 1.30, 95% CI = 1.03-1.64), while rs11599672 was associated with a significantly decreased risk (GG vs. TT: adjusted OR = 0.54, 95% CI = 0.34-0.86; TG/GG vs. TT: adjusted OR = 0.76, 95% CI = 0.61-0.95).

Conclusions

Our findings suggest that PLCE1 variants may have an effect on risk of SCCHN associated with tobacco and alcohol exposure, particularly for those tumors arising at non-oropharyngeal sites. These findings, although need to be validated by larger studies, are consistent with those in esophageal and gastric cancers.

Available only for authorised users

Marcu LG, Yeoh E: A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment. J Cancer Res Clin Oncol. 2009, 135 (10): 1303-1314. 10.1007/s00432-009-0648-7.CrossRefPubMed

Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed

Sturgis EM, Cinciripini PM: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?. Cancer. 2007, 110 (7): 1429-1435. 10.1002/cncr.22963.CrossRefPubMed

Neumann AS, Sturgis EM, Wei Q: Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog. 2005, 42 (2): 65-92. 10.1002/mc.20069.CrossRefPubMed

Ho T, Wei Q, Sturgis EM: Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck. 2007, 29 (7): 682-699. 10.1002/hed.20570.CrossRefPubMed

Carlson CS, Eberle MA, Kruglyak L, Nickerson DA: Mapping complex disease loci in whole-genome association studies. Nature. 2004, 429 (6990): 446-452. 10.1038/nature02623.CrossRefPubMed

Stadler ZK, Thom P, Robson ME, Weitzel JN, Kauff ND, Hurley KE, Devlin V, Gold B, Klein RJ, Offit K: Genome-Wide Association Studies of Cancer. J Clin Oncol. 2010, 28 (27): 4255-4267. 10.1200/JCO.2009.25.7816.CrossRefPubMedPubMedCentral

McKay JD, Truong T, Gaborieau V, Chabrier A, Chuang SC, Byrnes G, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Holcatova I, Janout V, Foretova L, Lagiou P, Trichopoulos D, Benhamou S, Bouchardy C, Ahrens W, Merletti F, Richiardi L, Talamini R, Barzan L, Kjaerheim K, Macfarlane GJ, Macfarlane TV, Simonato L, et al: A Genome-Wide Association Study of Upper Aerodigestive Tract Cancers Conducted within the INHANCE Consortium. PLoS Genet. 2011, 7 (3): e1001333-10.1371/journal.pgen.1001333.CrossRefPubMedPubMedCentral

Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, Li JM, Kong GQ, Qi H, Cui J, Zhang LQ, Yang JZ, Li JL, Li XC, Ren JL, Liu ZC, Gao WJ, Yuan L, Wei W, Zhang YR, Wang WP, Sheyhidin I, Li F, Chen BP, Ren SW, Liu B, Li D, Ku JW, Fan ZM, Zhou SL, et al: Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet. 2010, 42 (9): 759-763. 10.1038/ng.648.CrossRefPubMed

10.

Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, Yuan JM, Zheng W, Dawsey SM, Dong LM, Lee MP, Ding T, Qiao YL, Gao YT, Koh WP, Xiang YB, Tang ZZ, Fan JH, Wang C, Wheeler W, Gail MH, Yeager M, Yuenger J, Hutchinson A, Jacobs KB, Giffen CA, Burdett L, Fraumeni JF, Tucker MA, Chow WH, et al: A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet. 42 (9): 764-767.

11.

Wing MR, Bourdon DM, Harden TK: PLC-epsilon: a shared effector protein in Ras-, Rho-, and G alpha beta gamma-mediated signaling. Mol Interv. 2003, 3 (5): 273-280. 10.1124/mi.3.5.273.CrossRefPubMed

12.

Li M, Edamatsu H, Kitazawa R, Kitazawa S, Kataoka T: Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis. Carcinogenesis. 2009, 30 (8): 1424-1432. 10.1093/carcin/bgp125.CrossRefPubMed

13.

Bai Y, Edamatsu H, Maeda S, Saito H, Suzuki N, Satoh T, Kataoka T: Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development. Cancer Res. 2004, 64 (24): 8808-8810. 10.1158/0008-5472.CAN-04-3143.CrossRefPubMed

14.

Ou L, Guo Y, Luo C, Wu X, Zhao Y, Cai X: RNA interference suppressing PLCE1 gene expression decreases invasive power of human bladder cancer T24 cell line. Cancer Genet Cytogenet. 200 (2): 110-119.

15.

Wang X, Zbou C, Qiu G, Fan J, Tang H, Peng Z: Screening of new tumor suppressor genes in sporadic colorectal cancer patients. Hepatogastroenterology. 2008, 55 (88): 2039-2044.PubMed

16.

Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P: Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem. 2006, 281 (20): 14026-14040. 10.1074/jbc.M507734200.CrossRefPubMed

17.

Mehanna H, Paleri V, West CM, Nutting C: Head and neck cancer--Part 1: Epidemiology, presentation, and prevention. BMJ. 2010, 341: c4684-10.1136/bmj.c4684.CrossRefPubMed

18.

Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida R, Yoshinaga K, Saeki H, Emi Y, Kakeji Y, Sakaguchi Y, Toh Y, Maehara Y: Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol. 2010, 15 (2): 126-134. 10.1007/s10147-010-0056-7.CrossRefPubMed

19.

Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA: Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010, 59 (1): 39-48. 10.1136/gut.2009.191080.CrossRefPubMed

20.

Liu Z, Calderon JI, Zhang Z, Sturgis EM, Spitz MR, Wei Q: Polymorphisms of vitamin D receptor gene protect against the risk of head and neck cancer. Pharmacogenet Genomics. 2005, 15 (3): 159-165. 10.1097/01213011-200503000-00004.CrossRefPubMed

21.

Huang YJ, Niu J, Liu Z, Wang LE, Sturgis EM, Wei Q: The functional IGFBP7 promoter -418G > A polymorphism and risk of head and neck cancer. Mutat Res. 2010, 702 (1): 32-39.CrossRefPubMedPubMedCentral

22.

Xu Z, Taylor JA: SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009, 37 (Web Server issue): W600-605.CrossRefPubMedPubMedCentral

23.

Bunney TD, Baxendale RW, Katan M: Regulatory links between PLC enzymes and Ras superfamily GTPases: signalling via PLCepsilon. Adv Enzyme Regul. 2009, 49 (1): 54-58. 10.1016/j.advenzreg.2009.01.004.CrossRefPubMed

24.

Kelley GG, Reks SE, Ondrako JM, Smrcka AV: Phospholipase C(epsilon): a novel Ras effector. EMBO J. 2001, 20 (4): 743-754. 10.1093/emboj/20.4.743.CrossRefPubMedPubMedCentral

25.

Lopez I, Mak EC, Ding J, Hamm HE, Lomasney JW: A novel bifunctional phospholipase c that is regulated by Galpha 12 and stimulates the Ras/mitogen-activated protein kinase pathway. J Biol Chem. 2001, 276 (4): 2758-2765. 10.1074/jbc.M008119200.CrossRefPubMed

26.

Sorli SC, Bunney TD, Sugden PH, Paterson HF, Katan M: Signaling properties and expression in normal and tumor tissues of two phospholipase C epsilon splice variants. Oncogene. 2005, 24 (1): 90-100. 10.1038/sj.onc.1208168.CrossRefPubMed

27.

Gbadegesin R, Hinkes BG, Hoskins BE, Vlangos CN, Heeringa SF, Liu J, Loirat C, Ozaltin F, Hashmi S, Ulmer F, Cleper R, Ettenger R, Antignac C, Wiggins RC, Zenker M, Hildebrandt F: Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant. 2008, 23 (4): 1291-1297.CrossRefPubMed

28.

Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000, 92 (9): 709-720. 10.1093/jnci/92.9.709.CrossRefPubMed

29.

D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007, 356 (19): 1944-1956. 10.1056/NEJMoa065497.CrossRefPubMed

30.

Kreimer AR, Clifford GM, Boyle P, Franceschi S: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005, 14 (2): 467-475. 10.1158/1055-9965.EPI-04-0551.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/258/prepub

Title: Association between novel PLCE1variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck
Authors: Hongxia Ma
Li-E Wang
Zhensheng Liu
Erich M Sturgis
Qingyi Wei
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-11-258

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial

Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study

The usefulness and feasibility of a screening instrument to identify psychosocial problems in patients receiving curative radiotherapy: a process evaluation

Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling

SFRP1 reduction results in an increased sensitivity to TGF-β signaling

Keynote webinar | Spotlight on antibody–drug conjugates in cancer